N- (4- chlorophenyl)- N- (2- fluoro- 4- (2- oxopyridin- 1(2H)- yl)phenyl)- 4- methoxypyrrolidiine- 1,2- dicarboxamide

03/01/2008 - "PD0348292 completely inhibited thrombosis after venous stenting. "
03/01/2008 - "Thrombus weight and platelet deposition were significantly reduced by PD0348292 at 0.4 (49+/-79 mg and 110+/-145x10(6)/cm2), 0.9 (5+/-6 mg and 107+/-128x10(6)/cm2), 4.3 mg/kg (0+/-0 mg and 87+/-125x10(6)/cm2), and PD348292 plus aspirin (20+/-40 mg and 157+/-70x10(6)/cm2) compared with vehicle (402+/-226 mg; 584+/-454x10(6)/cm2). "
04/01/2008 - "In conclusion, PD0348292 inhibited arterial thrombosis comparable to aspirin plus clopidogrel. "
04/01/2008 - "Comparison of PD0348292, a selective factor Xa inhibitor, to antiplatelet agents for the inhibition of arterial thrombosis."
04/01/2008 - "The objective of this study was to determine if orally-administered PD0348292, a direct specific factor Xa inhibitor, inhibits thrombosis following porcine carotid arterial injury comparably to aspirin or clopidogrel alone or in combination. "

01/01/2016 - "Minor bleeding-related adverse events were observed following multiple doses of PD 0348292. "
08/01/2013 - "Total bleeding ranged from 4.9% to 13.8% across PD 0348292 doses and was 6.3% with enoxaparin. "

08/01/2013 - "To assess the efficacy and safety of a dose range of PD 0348292 relative to enoxaparin for the prevention of venous thromboembolism (VTE). "